A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)

Novartis

Status and phase: Completed; Phase 2

Conditions: Hypertension

Treatments: Drug: SPP100

Study type: Interventional

Funder types: Industry

Identifiers

NCT00246584

CSPP100A1202

Details and patient eligibility

About

This study will evaluate the safety and efficacy of long term treatment of SPP100 in patients with essential hypertension. (Trial is not recruiting in the US)

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed as essential hypertension -

Exclusion criteria

• Patients with secondary hypertension or suspected of having secondary hypertension.
• Patients suspected of having malignant hypertension
• Patients with any serious diseases or symptoms

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)